Biocon to acquire Biocon Biologics Limited from Serum Institute Life Sciences, Tata Capital, Activ Pine and Mylan for $6.315bn.

Biocon, global biopharmaceutical company, agreed to acquire Biocon Biologics Limited, a innovation-led global biopharmaceutical company, from Serum Institute Life Sciences, Tata Capital, Activ Pine and Mylan for $6.315bn. “The integration of Biocon Biologics Limited into Biocon Limited represents the next chapter in our evolution. Strategically, Biocon will be one of the few companies offering both biosimilars and generics at a global scale. As the only company with biosimilar insulins and generic GLP1 peptides, Biocon is uniquely positioned to comprehensively address the needs of patients living with diabetes. Together with our combined oncology and immunology portfolios, this creates a differentiated offering addressing the world’s most pressing healthcare needs. I am also pleased to announce that Shreehas Tambe will lead the Transition and Integration Management Committee and will take over as the CEO & Managing Director of the combined business, subject to requisite approvals. His 28 years of experience with the Biocon Group will be invaluable as we advance our mission to make lifesaving medicines affordable and accessible to patients worldwide,” Kiran Mazumdar-Shaw, Biocon Limited Executive Chairperson.